Clinical Trial Update: A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease [Phase 4]

View source ↗

Summary

Phase 4 dose-optimization study of Aldurazyme (Laronidase) in patients with Mucopolysaccharidosis I completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hurler Syndrome
• Hurler-scheie Syndrome
• Mucopolysaccharidosis Type
• Scheie Syndrome

Drugs mentioned

• Aldurazyme (Laronidase)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Mucopolysaccharidosis I, Hurler's Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2009-06-16